https://daikikumakura.github.io/2026-10-18https://daikikumakura.github.io/profile.htmlhttps://daikikumakura.github.io/writing.html2026-10-18https://daikikumakura.github.io/software.htmlhttps://daikikumakura.github.io/publication.htmlhttps://daikikumakura.github.io/activity.htmlhttps://daikikumakura.github.io/writing/on-treatment-immune-change.html2026-10-18https://daikikumakura.github.io/writing/borrowing-prior-dose-selection.html2026-10-17https://daikikumakura.github.io/writing/tumor-dropout-sensitivity.html2026-10-16https://daikikumakura.github.io/writing/tcell-engager-decision-framework.html2026-10-15https://daikikumakura.github.io/writing/sotorasib-dose-comparison.html2026-10-14https://daikikumakura.github.io/writing/sotorasib-dose-comparison-en.html2026-10-14https://daikikumakura.github.io/writing/immune-outcome-validation.html2026-10-13https://daikikumakura.github.io/writing/er-protac-pkpd.html2026-10-12https://daikikumakura.github.io/writing/er-protac-pkpd-en.html2026-10-12https://daikikumakura.github.io/writing/virtual-cell-target-evaluation.html2026-10-11https://daikikumakura.github.io/writing/nimotuzumab-poppk.html2026-10-10https://daikikumakura.github.io/writing/nimotuzumab-poppk-en.html2026-10-10https://daikikumakura.github.io/writing/tumor-kinetics-landmark.html2026-10-09https://daikikumakura.github.io/writing/tarlatamab-summary-pk.html2026-10-08https://daikikumakura.github.io/writing/tarlatamab-summary-pk-en.html2026-10-08https://daikikumakura.github.io/writing/ai-drug-discovery-bottlenecks.html2026-10-07https://daikikumakura.github.io/writing/tcell-engager-regimen-design.html2026-10-05https://daikikumakura.github.io/writing/tcell-engager-regimen-design-en.html2026-10-05https://daikikumakura.github.io/writing/warfarin-pkpd.html2026-10-04https://daikikumakura.github.io/writing/tumor-dynamics-survival.html2026-10-04https://daikikumakura.github.io/writing/mosunetuzumab-public-pk.html2026-10-02https://daikikumakura.github.io/writing/mosunetuzumab-public-pk-en.html2026-10-02https://daikikumakura.github.io/topics/population-pk-dosing-interval.html2026-10-15https://daikikumakura.github.io/topics/pk-pd-target-engagement.html2026-10-12https://daikikumakura.github.io/topics/dose-selection-benefit-risk.html2026-10-17https://daikikumakura.github.io/topics/tumor-dynamics-survival.html2026-10-16https://daikikumakura.github.io/topics/immune-biomarkers-response.html2026-10-18https://daikikumakura.github.io/topics/ai-drug-discovery-evidence.html2026-10-11https://daikikumakura.github.io/software/pkident.htmlhttps://daikikumakura.github.io/software/rsemflow.htmlhttps://daikikumakura.github.io/software/retiaudit.htmlhttps://daikikumakura.github.io/software/rlr-transform.htmlhttps://daikikumakura.github.io/software/crism.htmlhttps://daikikumakura.github.io/software/shotgunmetagenomics.htmlhttps://daikikumakura.github.io/software/dockerfiles.html